-
1تقرير
المؤلفون: Celgene, Genentech, Inc.
المساهمون: Beth Christian, Principal Investigator
المصدر: A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT02992522Test
Other URLs: http://cancer.osu.eduTest
-
2تقرير
المؤلفون: Gilead Sciences
المساهمون: Beth Christian, Principal Investigator
المصدر: Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2015 Jun;169(5):701-10. doi: 10.1111/bjh.13354. Epub 2015 Apr 7.
A Phase I/II Study of Veltuzumab (IMMU-106, hA20), a Humanized Anti-CD20 Monoclonal Antibody, Combined With Milatuzumab (IMMU-115, hLL1), a Humanized Anti-CD74 Monoclonal Antibody, in Relapsed and Refractory B-cell Non-Hodgkin's Lymphomaالوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00989586Test
Other URLs: http://cancer.osu.eduTest
-
3تقرير
المساهمون: Beth Christian, Principal Investigator
المصدر: Cohen JB, WeL, Maddocks KJ, Chrtn B, Heffner LT, Langston AA, Lechowz MJ, Porcu P, Flowers CR, Deve SM, Blum KA. Gemcabe and bendamuste a safe and effecte salvage regen for patnts wh recurrent/refractory Hodgk lymphoma: Results of a phase 1/2 study. Cancer. 2020 Mar 15;126(6):1235-1242. do 10.1002/cncr.32640. Epub 2019 Dec 10.
A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphomaالوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01535924Test
Other URLs: http://cancer.osu.eduTest
